According to Persistence Market Research the global Preclinical Contract Research Organization (CRO) Market is witnessing substantial growth, driven by increasing research and development activities in the pharmaceutical and biotechnology sectors. As of 2025, the market is valued at US$ 5,722.7 million, and is projected to reach US$ 10,528.7 million by 2032, growing at a CAGR of 9.1%. This surge is attributed to the expanding demand for outsourcing preclinical services, driven by rising costs and complexity in drug discovery.

The toxicology testing segment is expected to lead the market, growing at a CAGR of 10% during the forecast period. This dominance is largely due to the increasing regulatory scrutiny, the essential role of toxicology in Investigational New Drug (IND)-enabling studies, and the rise in outsourcing noncore studies by pharmaceutical companies.

Geographically, North America holds the largest share of the preclinical CRO market. The U.S., in particular, is driving growth with robust biopharmaceutical activity, high R&D investments, and a well-established regulatory framework. Furthermore, the presence of leading CRO players and advanced infrastructure in the region supports market expansion. However, the Asia Pacific region is anticipated to grow at the fastest pace, bolstered by lower operational costs, skilled labor, and supportive government initiatives in countries like India, China, and Singapore.